

## THE DISTILLERY

## This week in therapeutics

Indication	Target/marker/pathway	Summary	Licensing status	Publication and contact information
Autoimmune disease				
Inflammatory bowel disease (IBD)	Not applicable	Mouse studies identified a combination of 17 <i>Clostridia</i> strains (17-mix) that could help treat inflammatory bowel disease. In germ-free mice, inoculation with human fecal samples led to identification of 17 <i>Clostridia</i> strains that increased the population of colonic $T_{reg}$ cells compared with no inoculation. In a mouse model of allergic diarrhea, 17-mix reduced the occurrence and severity of diarrhea compared with vehicle. In a mouse model of colitis, 17-mix decreased colon shortening and normalized colonic histology compared with vehicle. Next steps include testing 17-mix in other preclinical models of inflammatory bowel disease. Vedanta Biosciences Inc. has 17-mix in preclinical development to treat inflammatory bowel disease.	Patented by University of Tokyo; licensed to Vedanta Biosciences Inc.	Atarashi, K. <i>et al. Nature</i> ; published online July 10, 2013; doi:10.1038/nature12331 <b>Contact:</b> Kenya Honda, RIKEN Center for Integrative Medical Sciences, Yokohama, Japan e-mail: kenya@rcai.riken.jp

*SciBX* 6(31); doi:10.1038/scibx.2013.816 Published online Aug. 15, 2013